Cargando…
Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-γ Agonist
Drug binding to plasma proteins restricts their free and active concentrations, thereby affecting their pharmacokinetic properties. Species differences in plasma protein levels complicate the understanding of interspecies pharmacodynamic and toxicological effects. MBX-102 acid/JNJ39659100 is a novel...
Autores principales: | Clarke, Holly J., Gregoire, Francine, Ma, Fang, Martin, Robert, Zhao, Spring, Lavan, Brian E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2535826/ https://www.ncbi.nlm.nih.gov/pubmed/18815616 http://dx.doi.org/10.1155/2008/465715 |
Ejemplares similares
-
MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-γ Agonist Lowers Triglyceride Independently of PPAR-α Activation
por: Chandalia, Apurva, et al.
Publicado: (2009) -
MMPP promotes adipogenesis and glucose uptake via binding to the PPARγ ligand binding domain in 3T3-L1 MBX cells
por: Kim, Na-Yeon, et al.
Publicado: (2022) -
Selective Modulators of PPAR-γ Activity: Molecular Aspects Related to Obesity and Side-Effects
por: Zhang, Fang, et al.
Publicado: (2007) -
Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021) -
Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)